share_log

AbbVie | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

AbbVie | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

艾伯維公司 | S-8：員工福利計劃證券登記
美股SEC公告 ·  11/04 13:21

Moomoo AI 已提取核心訊息

AbbVie Inc., a biopharmaceutical company incorporated in Delaware, has filed a Registration Statement on Form S-8 with the United States Securities and Exchange Commission (SEC) on November 4, 2024. The purpose of this filing is to register additional shares of common stock that may be offered or sold under the AbbVie Savings Program. This program is designed for employee participation and the registration also covers an indeterminate amount of plan interests. The filing is in accordance with General Instruction E to Form S-8, which pertains to the registration of additional securities. AbbVie Inc. has referenced its prior Registration Statement from December 19, 2012, and has included exhibits detailing its corporate governance documents and the consent of Ernst & Young LLP. The company has confirmed compliance with IRS regulations for the AbbVie Savings Program to qualify under Section 401 of the U.S. Internal Revenue Code. The Registration Statement has been signed by key executives including the CEO, CFO, and other directors of AbbVie Inc.
AbbVie Inc., a biopharmaceutical company incorporated in Delaware, has filed a Registration Statement on Form S-8 with the United States Securities and Exchange Commission (SEC) on November 4, 2024. The purpose of this filing is to register additional shares of common stock that may be offered or sold under the AbbVie Savings Program. This program is designed for employee participation and the registration also covers an indeterminate amount of plan interests. The filing is in accordance with General Instruction E to Form S-8, which pertains to the registration of additional securities. AbbVie Inc. has referenced its prior Registration Statement from December 19, 2012, and has included exhibits detailing its corporate governance documents and the consent of Ernst & Young LLP. The company has confirmed compliance with IRS regulations for the AbbVie Savings Program to qualify under Section 401 of the U.S. Internal Revenue Code. The Registration Statement has been signed by key executives including the CEO, CFO, and other directors of AbbVie Inc.
艾伯維公司是一家在特拉華州註冊成立的生物製藥公司，於2024年11月4日向美國證券交易委員會（SEC）提交了S-8表格的註冊聲明。此次申報的目的是註冊可能在艾伯維儲蓄計劃下提供或銷售的額外普通股。該計劃旨在員工參與，註冊內容還包括不定數量的計劃權益。該申報符合S-8表格的E條總則，涉及額外證券的註冊。艾伯維公司參考了其2012年12月19日的先前註冊聲明，並附上了詳細說明其公司治理文件及安永會計師事務所的同意。該公司已確認遵守了美國內部收入法典第401節的IRS法規，以符合艾伯維儲蓄計劃的資格。註冊聲明已由首席執行官、首席財務官和艾伯維公司的其他董事簽署。
艾伯維公司是一家在特拉華州註冊成立的生物製藥公司，於2024年11月4日向美國證券交易委員會（SEC）提交了S-8表格的註冊聲明。此次申報的目的是註冊可能在艾伯維儲蓄計劃下提供或銷售的額外普通股。該計劃旨在員工參與，註冊內容還包括不定數量的計劃權益。該申報符合S-8表格的E條總則，涉及額外證券的註冊。艾伯維公司參考了其2012年12月19日的先前註冊聲明，並附上了詳細說明其公司治理文件及安永會計師事務所的同意。該公司已確認遵守了美國內部收入法典第401節的IRS法規，以符合艾伯維儲蓄計劃的資格。註冊聲明已由首席執行官、首席財務官和艾伯維公司的其他董事簽署。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間